Pfizer Inc. Stock

Humans are very bad at taking medications. By some estimates, adherence to long-term chronic medication treatment plans is only around 50%. This is a big issue for GLP-1 weight-loss drugs, which

Dividend investing is a proven way to earn above-average long-term returns. That's why top dividend stocks often attract large crowds of investors and trade at a premium. However, it's possible to

It's hard not to love high dividend yields. Who doesn't want more dividends for their money? Pfizer (NYSE: PFE) and its current yield of 7% will certainly grab your attention.

But remember that the

Pfizer's (NYSE: PFE) shares have significantly underperformed broader equities over the past three years. The company's reliance on its coronavirus portfolio has been a weakness, as vaccination

Although its growth rate has been cause for concern for investors in recent years, Pfizer (NYSE: PFE) is a stock that I don't think you should count out right now. The company is in the midst of a

Pfizer's (NYSE: PFE) shares have lost more than 50% of their value since late 2021 due to poor financial results. The company has tried to bounce back. Notably, it has expanded its pipeline through

Pfizer (NYSE: PFE) is offering dividend investors a huge 6.9% yield. To put that into perspective, the S&P 500 index (SNPINDEX: ^GSPC) has a tiny 1% yield right now, and the average pharmaceutical

Looking for stocks that pay dividends? You may have come across pharmaceutical outfit Pfizer (NYSE: PFE) in your search. After all, its forward-looking dividend yield of 7.1% is one of the highest

Acquisitions can be a double-edged sword for companies, as they can quickly bolster revenue and growth opportunities but also add costs and inefficiencies. Healthcare giant Pfizer (NYSE: PFE) has

Pfizer (NYSE: PFE) is deeply unloved, down more than 50% from its late 2021 high. The stock decline has driven the dividend yield up to a very high 6.8%, well above the pharmaceutical stock average

Eli Lilly (NYSE: LLY) is basically hitting it out of the park right now. Sales of its industry-leading GLP-1 weight-loss drugs Mounjaro and Zepbound rose 125% and 80%, respectively, in the first

If it weren't for question marks about its future growth, Pfizer (NYSE: PFE) stock would undoubtedly be trading at a much higher price. Sales were down last year, and the stock has been floundering,

Pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are still the two titans of the weight loss drug market, to be sure. Lilly sold $13.5 billion worth of GLP-1-based Zepbound

If you keep regular tabs on pharmaceutical giant Pfizer (NYSE: PFE), then you know it hasn't yet restored the revenue lost due to the wind-down of the COVID-19 pandemic; the world just doesn't need

The S&P 500 index (SNPINDEX: ^GSPC) has a tiny yield of 1.1%. The average pharmaceutical company's yield is 1.7%. Those comparison points make Pfizer's (NYSE: PFE) 6.7% dividend yield look

When it comes to pharmaceutical stocks and yield, Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) stand out. However, when deciding which of the two is the better high-yield dividend stock

If you have $1,000 that you can afford to invest in the stock market, dividend stocks can help make the most of your money, specifically those that are trading at low valuations. While buying Nvidia